PMID- 32982371
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220417
IS  - 1178-7031 (Print)
IS  - 1178-7031 (Electronic)
IS  - 1178-7031 (Linking)
VI  - 13
DP  - 2020
TI  - Treatment of Recurrent Clostridioides difficile Infection Using Fecal Microbiota 
      Transplantation in Iranian Patients with Underlying Inflammatory Bowel Disease.
PG  - 563-570
LID - 10.2147/JIR.S265520 [doi]
AB  - PURPOSE: Fecal microbiota transplantation (FMT) is an effective treatment option 
      for patients with recurrent Clostridioides difficile infection (rCDI). However, 
      there is a paucity of evidence regarding its efficacy and safety in patients with 
      rCDI and concurrent inflammatory bowel disease (IBD). Here, we present a 
      single-center experience of FMT for treatment of rCDI in Iranian patients with 
      IBD. PATIENTS AND METHODS: Eight patients with established IBD (7 with ulcerative 
      colitis and 1 with Crohn's disease) who underwent at least one FMT via 
      colonoscopy for treatment of rCDI were enrolled in this study. Demographics, 
      pre-FMT and post-FMT IBD activity, efficacy for rCDI and adverse events (AEs) 
      were assessed during a 6-month follow-up period. All patients had experienced 3 
      episodes of rCDI and were refractory to conventional therapies with metronidazole 
      and vancomycin. Primary cure and secondary cure rates were assessed after FMT 
      treatments. RESULTS: A total of 10 FMTs were performed via colonoscopy in 8 
      patients (6/8; 75% men) with a median age of 35 years (range: 22-60). Two 
      patients received a second FMT. Overall, the primary and secondary cure rates 
      were 75% and 100%, respectively. Two patients developed CPE-producing C. 
      perfringens diagnoses after second FMTs. There were no other AEs, and no patient 
      experienced IBD flare. CONCLUSION: We demonstrated that FMT appears to be an 
      effective, safe and rational therapeutic alternative for resolution of rCDI in 
      patients with underlying IBD. Furthermore, we suggest implementing the 
      CPE-producing C. perfringens testing in the screening of FMT donors.
CI  - (c) 2020 Azimirad et al.
FAU - Azimirad, Masoumeh
AU  - Azimirad M
AUID- ORCID: 0000-0002-2983-7117
AD  - Foodborne and Waterborne Diseases Research Center, Research Institute for 
      Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical 
      Sciences, Tehran, Iran.
FAU - Yadegar, Abbas
AU  - Yadegar A
AUID- ORCID: 0000-0002-2135-7581
AD  - Foodborne and Waterborne Diseases Research Center, Research Institute for 
      Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical 
      Sciences, Tehran, Iran.
FAU - Gholami, Fatemeh
AU  - Gholami F
AD  - Foodborne and Waterborne Diseases Research Center, Research Institute for 
      Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical 
      Sciences, Tehran, Iran.
FAU - Shahrokh, Shabnam
AU  - Shahrokh S
AD  - Gastroenterology and Liver Diseases Research Center, Research Institute for 
      Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical 
      Sciences, Tehran, Iran.
FAU - Asadzadeh Aghdaei, Hamid
AU  - Asadzadeh Aghdaei H
AUID- ORCID: 0000-0001-5589-8856
AD  - Basic and Molecular Epidemiology of Gastrointestinal Disorders Research Center, 
      Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti 
      University of Medical Sciences, Tehran, Iran.
FAU - Ianiro, Gianluca
AU  - Ianiro G
AD  - Digestive Disease Center, Fondazione Policlinico Universitario Agostino Gemelli 
      IRCCS, Catholic University of Sacred Heart, Rome, Italy.
FAU - Suzuki, Hidekazu
AU  - Suzuki H
AUID- ORCID: 0000-0002-8994-6163
AD  - Division of Gastroenterology and Hepatology, Department of Internal Medicine, 
      Tokai University School of Medicine, Isehara, Kanagawa 259-1193, Japan.
FAU - Cammarota, Giovanni
AU  - Cammarota G
AD  - Digestive Disease Center, Fondazione Policlinico Universitario Agostino Gemelli 
      IRCCS, Catholic University of Sacred Heart, Rome, Italy.
FAU - Zali, Mohammad Reza
AU  - Zali MR
AD  - Gastroenterology and Liver Diseases Research Center, Research Institute for 
      Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical 
      Sciences, Tehran, Iran.
LA  - eng
PT  - Journal Article
DEP - 20200918
PL  - New Zealand
TA  - J Inflamm Res
JT  - Journal of inflammation research
JID - 101512684
PMC - PMC7509309
OTO - NOTNLM
OT  - FMT
OT  - IBD
OT  - Iran
OT  - fecal microbiota transplantation
OT  - inflammatory bowel disease
OT  - rCDI
OT  - recurrent Clostridioides difficile infection
COIS- Prof. Dr. Hidekazu Suzuki reports grants, personal fees from Takeda, personal 
      fees from Astellas, personal fees from AstraZeneca, grants from Daiichi-Sankyo, 
      outside the submitted work. The authors declare that they have no other potential 
      conflicts of interest for this work.
EDAT- 2020/09/29 06:00
MHDA- 2020/09/29 06:01
PMCR- 2020/09/18
CRDT- 2020/09/28 05:37
PHST- 2020/06/01 00:00 [received]
PHST- 2020/09/07 00:00 [accepted]
PHST- 2020/09/28 05:37 [entrez]
PHST- 2020/09/29 06:00 [pubmed]
PHST- 2020/09/29 06:01 [medline]
PHST- 2020/09/18 00:00 [pmc-release]
AID - 265520 [pii]
AID - 10.2147/JIR.S265520 [doi]
PST - epublish
SO  - J Inflamm Res. 2020 Sep 18;13:563-570. doi: 10.2147/JIR.S265520. eCollection 
      2020.